150
Participants
Start Date
August 15, 2022
Primary Completion Date
October 16, 2023
Study Completion Date
November 20, 2023
Semaglutide 2.4 mg
Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
Placebo (semaglutide 2.4 mg)
Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
King Chulalongkorn Memorial Hospital_Bangkok, Bangkok
King Chulalongkorn Memorial Hospital_Endocrinology, Bangkok
King Chulalongkorn Memorial Hospital_Obstetrics&Gynecology, Bangkok
Obstetrics&Gynecology King Chulalongkorn Memorial Hospital, Bangkok
RAMA - Division of Nutrition and Biochemical Medicine, Bangkok
Siriraj Hospital-Cardio, Bangkok
Siriraj Hospital_Bangkok_1, Bangkok
Siriraj Institute of Clinical Research, Bangkok
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do
Hallym University Sacred Heart Hospital, Gyeonggi-do
Ajou University Hospital, Suwon
Konyang University Hospital, Daejeon
CMU - Hematology and Oncology, Chiang Mai
Gachon University Gil Hospital, Incheon
SMG-SNU Boramae Medical Center, Seoul
Lead Sponsor
Novo Nordisk A/S
INDUSTRY